155 related articles for article (PubMed ID: 35447198)
1. The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against atherosclerosis by suppressing EndMT via modulating Akt1/β-catenin signaling pathway.
Diao H; Cheng J; Huang X; Huang B; Shao X; Zhao J; Lan D; Zhu Q; Yan M; Zhang Y; Rong X; Guo J
J Ethnopharmacol; 2022 Jul; 293():115261. PubMed ID: 35447198
[TBL] [Abstract][Full Text] [Related]
2. Chinese medicine Fufang Zhenzhu Tiaozhi capsule ameliorates coronary atherosclerosis in diabetes mellitus-related coronary heart disease minipigs.
Wang L; Zhang D; Zhan W; Zeng Z; Yin J; Wang K; Wang H; Song L; Gu Z; Guo C; Zhong Q; Wang W; Rong X; Bei W; Guo J
Biomed Pharmacother; 2022 Dec; 156():113831. PubMed ID: 36228370
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
4. Fufang Zhenzhu Tiaozhi (FTZ) capsule ameliorates diabetes-accelerated atherosclerosis via suppressing YTHDF2-mediated m
Zhang Y; Wang R; Tan H; Wu K; Hu Y; Diao H; Wang D; Tang X; Leng M; Li X; Cai Z; Luo D; Shao X; Yan M; Chen Y; Rong X; Guo J
J Ethnopharmacol; 2023 Dec; 317():116766. PubMed ID: 37343655
[TBL] [Abstract][Full Text] [Related]
5. The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against renal injury and inflammation in mice with diabetic kidney disease.
Yang YQ; Tan HB; Zhang XY; Zhang YZ; Lin QY; Huang MY; Lin ZY; Mo JZ; Zhang Y; Lan T; Bei WJ; Guo J
J Ethnopharmacol; 2022 Jun; 292():115165. PubMed ID: 35247475
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MALAT1 modulates ox-LDL induced EndMT through the Wnt/β-catenin signaling pathway.
Li H; Zhao Q; Chang L; Wei C; Bei H; Yin Y; Chen M; Wang H; Liang J; Wu Y
Lipids Health Dis; 2019 Mar; 18(1):62. PubMed ID: 30871555
[TBL] [Abstract][Full Text] [Related]
7. Fufang Zhenzhu Tiaozhi (FTZ) suppression of macrophage pyroptosis: Key to stabilizing rupture-prone plaques.
Shao X; Zeng W; Wang Q; Liu S; Guo Q; Luo D; Luo Q; Wang D; Wang L; Zhang Y; Diao H; Piao S; Yan M; Guo J
J Ethnopharmacol; 2024 Apr; 324():117705. PubMed ID: 38219878
[TBL] [Abstract][Full Text] [Related]
8. The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease.
Song L; Zhang D; Guo C; Gu Z; Wang L; Yao YS; Wang H; Zeng Z; Wang W; Yang Y; Bei W; Rong X; Guo J
Biomed Pharmacother; 2021 May; 137():111343. PubMed ID: 33761594
[TBL] [Abstract][Full Text] [Related]
9. Fufang-zhenzhu-tiaozhi formula protects islet against injury and promotes β cell regeneration in diabetic mice.
Chen X; Yin J; Zhong Q; Wang K; Zhang X; Liang M; Lin Q; Wang H; Wang W; Wang L; Hu X; Bei W; Guo J
J Ethnopharmacol; 2023 Jan; 301():115791. PubMed ID: 36240976
[TBL] [Abstract][Full Text] [Related]
10. Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits.
Zhang R; Li T; Guo J; Zhao Y; Liu Y; Yao Y; Zeng Z
Lipids Health Dis; 2018 Nov; 17(1):272. PubMed ID: 30497486
[TBL] [Abstract][Full Text] [Related]
11. Longxuetongluo capsule inhibits atherosclerosis progression in high-fat diet-induced ApoE
Zheng J; Liu B; Lun Q; Gu X; Pan B; Zhao Y; Xiao W; Li J; Tu P
Atherosclerosis; 2016 Dec; 255():156-163. PubMed ID: 27591127
[TBL] [Abstract][Full Text] [Related]
12. Fufang-Zhenzhu-Tiaozhi capsule ameliorates rabbit's iliac artery restenosis by regulating adiponectin signaling pathway.
Li T; Zhang R; Liu Y; Yao Y; Guo J; Zeng Z
Biomed Pharmacother; 2020 Aug; 128():110311. PubMed ID: 32502838
[TBL] [Abstract][Full Text] [Related]
13. The Chinese herbal medicine Fufang Zhenzhu Tiaozhi ameliorates diabetic cardiomyopathy by regulating cardiac abnormal lipid metabolism and mitochondrial dynamics in diabetic mice.
Yan M; Liu S; Zeng W; Guo Q; Mei Y; Shao X; Su L; Liu Z; Zhang Y; Wang L; Diao H; Rong X; Guo J
Biomed Pharmacother; 2023 Aug; 164():114919. PubMed ID: 37302318
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of β-catenin prevents EndMT in vitro and vascular remodeling in vivo resulting from endothelial Akt1 suppression.
Sabbineni H; Verma A; Artham S; Anderson D; Amaka O; Liu F; Narayanan SP; Somanath PR
Biochem Pharmacol; 2019 Jun; 164():205-215. PubMed ID: 30991049
[TBL] [Abstract][Full Text] [Related]
15. MiR-200c-3p promotes ox-LDL-induced endothelial to mesenchymal transition in human umbilical vein endothelial cells through SMAD7/YAP pathway.
Mao Y; Jiang L
J Physiol Sci; 2021 Sep; 71(1):30. PubMed ID: 34525946
[TBL] [Abstract][Full Text] [Related]
16. [The effect of fufang zhenzhu tiaozhi capsule on lipid metabolism in atherosclerotic rabbits].
Tang CP; Jiang T; Guo J; Wei YP; Yang CY; Chen FC
Zhong Yao Cai; 2010 Aug; 33(8):1285-9. PubMed ID: 21213542
[TBL] [Abstract][Full Text] [Related]
17. Fufang Zhenzhu Tiaozhi capsule ameliorates hyperuricemic nephropathy by inhibition of PI3K/AKT/NF-κB pathway.
Li MH; Guan J; Chen Z; Mo JX; Wu KR; Hu XG; Lan T; Guo J
J Ethnopharmacol; 2022 Nov; 298():115644. PubMed ID: 35987412
[TBL] [Abstract][Full Text] [Related]
18. Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis.
Lan T; Xu T; Fu Y; Jiang S; Liang X; Yu Z; Pan L; Rong X; Guo J
Front Endocrinol (Lausanne); 2022; 13():864703. PubMed ID: 35784533
[TBL] [Abstract][Full Text] [Related]
19. Traditional Chinese Medicine Fufang-Zhenzhu-Tiaozhi capsule prevents renal injury in diabetic minipigs with coronary heart disease.
Song L; Wang K; Yin J; Yang Y; Li B; Zhang D; Wang H; Wang W; Zhan W; Guo C; Gu Z; Wang L; Zeng Z; Bei W; Rong X; Guo J
Chin Med; 2022 Aug; 17(1):102. PubMed ID: 36042482
[TBL] [Abstract][Full Text] [Related]
20. The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation.
Yan M; Li L; Wang Q; Shao X; Luo Q; Liu S; Li Y; Wang D; Zhang Y; Diao H; Rong X; Guo J
Biomed Pharmacother; 2022 Apr; 148():112709. PubMed ID: 35190353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
